Genetics, risk factors and COVID-19
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-385
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
UK Research and Innovation (UKRI)Principal Investigator
Dr. Stephen BurgessResearch Location
United KingdomLead Research Institution
MRC Biostatistics UnitResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Prophylactic use of treatmentsSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Randomized Controlled TrialBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
How can we answer questions of causation ("what if?" questions) when we can't perform experiments directly? In the case of COVID-19, a typical causal question would look like this: what would happen if we prescribed people anti-inflammatory medications? Would it improve outcomes? While we can answer these questions definitively by performing a randomized trial, this approach is slow. With this outbreak, time is of the essence and there are many potential treatments to evaluate. Instead of performing the randomization ourselves, our approach is to exploit a randomization that nature has provided for us in genetics.